Experts red-flag cancer drug price cuts as patented therapies see zero relief, markups exceed benchmark
Experts said there should be comprehensive, cost-based price controls covering all oncology therapies, permanent statutory margin caps across distribution channels and full scrutiny of company assistance programmes.
We haven't written up this one. Live Mint has the full story — the link below goes straight to it.